Claims
- 1. An amino acid derivative of the formula ##STR15## wherein R.sup.1 is hydrogen or an optionally phenyl-substituted alkyl group with 1 to 6 carbon atoms;
- R.sup.2 is hydrogen or an optionally phenyl-substituted alkyl group with 1 to 4 carbon atoms;
- R.sup.3 is hydrogen, an alkyl group with 1 to 7 carbon atoms which may have an amino group or a phenyl ring in the terminal position, or the group R.sup.4 --CO--;
- R.sup.4 is an alkyl group with 1 to 5 carbon atoms, which, when W=NH, may have an amino group in the .alpha. position;
- W is oxygen, sulphur or an NH group;
- n and m are each 0, 1, or 2, the sum of n and m being 1 or 2;
- k is 1, 2, 3 or 4;
- A is the group ##STR16## which may be linked to the ring B in either way; or a pharmaceutically acceptable salt thereof.
- 2. A compound as claimed in claim 1, having the formula ##STR17## wherein m is 1 or 2, and
- n is 0 or 1, the sum of m+n being equal to 2.
- 3. A compound as claimed in claim 1, having the formula ##STR18## wherein R.sup.2 'is H or C.sub.1-4 alkyl and
- R.sup.3 'is H or COR.sup.4 , wherein R4 is as hereinbefore defined,
- m is 1 or 2, and
- n is 0 or 1, the sum of m+n equaling 2.
- 4. A compound as claimed in claims 1, 2 or 3, characterized in that all the centers of asymmetry occur in the L-form.
- 5. In accordance with claim 1, N-[N-(1(S)-Ethoxycarbonyl-3-phenylpropyl)-L-lysyl]-4,5,6,7-tetrahydro-thieno]3,2-c]pyridine-4(S)-carboxylic acid, or a pharmaceutically acceptable salt thereof.
- 6. In accordance with claim 1, N-[N-(1(S)-Ethoxycarbonyl-3-phenylpropyl)-L-lysyl]-4,5,6,7-tetrahydro-thieno[2,3-c]]pyridine-7(S)-carboxylic acid, or a pharmaceutically acceptable salt thereof.
- 7. In accordance with claim 1, N-[N-(1S)-Carboxy-3-phenylpropyl)-L-Lysyl]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-5(S)-carboxylic acid, or a pharmaceutically acceptable salt thereof.
- 8. In accordance with claim 1, N-[N-(1(S)-Carboxy-3-phenylpropyl)Llysyl]-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine-6(S)-carboxylic acid, or a pharmaceutically acceptable salt thereof.
- 9. In accordance with claim 1, N-[N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-lysyl]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-5(S)-carboxylic acid, or a pharmaceutically acceptable salt thereof.
- 10. In accordance with claim 1, N-[N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-lysyl]-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine-6(S)-carboxylic acid, or a pharmaceutically acceptable salt thereof.
- 11. In accordance with claim 1, N-[N-(1(S)-Carboxy-3-phenylpropyl)-L-lysyl]-4,5,6,7-tetrahydro-thieno[3,2-]pyridine-6(R)-carboxylic acid, or a pharmaceutically acceptable salt thereof.
- 12. A pharmaceutical preparation containing a compound of formula I as claimed in claim 1, or a salt thereof, and a pharmaceutically acceptable carrier.
- 13. A pharmaceutical preparation containing a compound of formula I, as claimed in claim 1, or a salt thereof, in admixture with a saluretic, diuretic or antihypertensive agent.
- 14. A method for treating high blood pressure, the prevention of infarction or reducing the myocardial oxygen consumption which comprise administering an effective amount of a compound of formula I, as claimed in claim 1, or a pharmaceutically acceptable salt thereof.
Priority Claims (1)
Number |
Date |
Country |
Kind |
3529960 |
Aug 1985 |
DEX |
|
Parent Case Info
This is a division of application Ser. No. 284,164, filed Dec. 14, 1988, now abandoned, which in turn is a continuation of application Ser. No. 127,751 filed Dec. 2, 1987, now abandoned which in turn is a continuation of application Ser. No. 897,444, filed Aug. 18, 1986, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4555511 |
Schnorrenberg et al. |
Nov 1985 |
|
Divisions (1)
|
Number |
Date |
Country |
Parent |
284164 |
Dec 1988 |
|
Continuations (2)
|
Number |
Date |
Country |
Parent |
127750 |
Dec 1987 |
|
Parent |
897444 |
Aug 1986 |
|